Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PET Trial For Alzheimer’s Opens Door For CMS-Backed Research – Phurrough

This article was originally published in The Gray Sheet

Executive Summary

CMS' decision to fund the full costs of clinical trials assessing positron emission tomography to diagnose Alzheimer's disease marks a step toward the establishment of trial coverage as a viable national coverage decision alternative for the agency
Advertisement

Related Content

CMS-Supported Clinical Data Collection Worth The Cost – Tunis
CMS-Supported Clinical Data Collection Worth The Cost – Tunis
CMS To Help Build National FDG-PET Cancer Registry, Will Cover Trials
CMS To Help Build National FDG-PET Cancer Registry, Will Cover Trials
TMR + CABG Trial Data Reveal Little About Procedure’s Efficacy – MCAC
TMR + CABG Trial Data Reveal Little About Procedure’s Efficacy – MCAC
Medicare Will Cover PET To Distinguish Alzheimer’s From Other Dementia
Medicare Will Cover PET To Distinguish Alzheimer’s From Other Dementia
Advertisement
UsernamePublicRestriction

Register

MT020552

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel